Searched for
PHARMA WOCKHARDT
Ahead of Market: 10 things that will decide stock market action on FridayIndian equities witnessed sharp swings before ending lower amid expiry-day volatility and rising geopolitical concerns. Profit booking in b...- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Pharma in her DNA, Wockhardt scion ready for deep dive in the USZahabiya Khorakiwala is leading Wockhardt's US business and the launch of its new antibiotic, Zaynich. This drug targets resistant bacteria...
- Zaynich's blockbuster potential lifts Wockhardt's long-term outlookWockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of n...
- Delhi HC allows Intas to sell cancer drug Bevatas, sets aside order favouring Sun PharmaThe Delhi High Court division bench has ruled in favor of Intas Pharmaceuticals, allowing the company to introduce its anti-cancer medicati...
- If you have the patience, you can achieve innovation milestones, says Wockhardt chairman Habil KhorakiwalaWockhardt Hospitals is set to launch its antibiotic Zaynich in the US. Zahabiya Khorakiwala will lead US operations. The drug is expected t...
- Ahead of Market: 10 things that will decide stock market action on TuesdayBenchmark indices Sensex and Nifty fell for a fourth straight session amid elevated crude oil prices, geopolitical tensions and persistent ...
- Ahead of Market: 10 things that will decide stock market action on MondayIndian equity markets ended sharply lower on May 29 amid broad-based selling, MSCI-driven flows and rising volatility. Technical indicators...
- Wockhardt shares jump 8%, extend rally after CDSCO nod for Zaynich antibioticWockhardt shares surged after the company received CDSCO approval for its breakthrough antibiotic Zaynich in India. Strong Phase 3 trial re...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Geopolitical tensions keep markets nervous despite strong earnings: Dipan MehtaGeopolitical tensions, particularly the Iran crisis, are overshadowing strong corporate earnings, according to Dipan Mehta. While India Inc...
- Ahead of Market: 10 things that will decide stock market action on ThursdayDomestic equities surged as crude oil slipped below $100 and US-India trade optimism boosted sentiment. Nifty and Sensex gained over 1%, le...
- Small & midcaps rally! Wockhardt, Coforge, other stocks surge up to 14%. Do you own any?Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...
- Will restructuring US biz turnaround this pharma player?In a regulatory filing, the company said it is closing down its manufacturing facility in Illinois, USA and will continue its business in t...
- Buy Wockhardt Pharma with target of Rs 1040: Mitesh Thacker"Wockhardt Pharma is a 'BUY' call with a target of Rs 1040 and a stop loss of Rs 964."
- Sell Wockhardt Pharma Ltd with target of Rs 188: Sandeep WagleIn a chat with ET Now, Sandeep Wagle, Founder & CEO of Power My Wealth, shares his view on Wockhardt Pharma Ltd.
- Sun flouted foreign currency norms, Wockhardt tells RBIWockhardt has drawn RBIs attention to possible violation of foreign currency laws by Sun Pharma.
- No wrongful motive in Wockhardt case, says Sun PharmaSun Pharma has sought to address concerns raised by Wockhardt that professional rivalry was behind its move to acquire FCCBs in the company.
- Sun Pharma and Wockhardt not safe bets: Ashish MaheshwariThere will be a slight blow for Wockhardt stock price and this may come down to 200-215 levels.
- Sun Pharma opposes Wockhardt dealMumbai-based Sun Pharmaceutical has challenged the settlement between Wockhardt and some of its creditors. Sun Pharma has claimed it holds ...
Load More
